Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
R115866 dose-ranging study in plaque psoriasis
2005-004623-19Phase 2Completed
- Sponsor
- Barrier Therapeutics, Inc.
- Start
- Dec 2005
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, single-blind trial of talarozole in plaque psoriasis (4 arms), sponsored by Barrier Therapeutics, Inc. Primary endpoint: PASI75 response at week 12. Started Dec 2005; status: completed.
02
Drugs
talarozole
03
Conditions
plaque psoriasis
Beyond the preview
Go deeper on 2005-004623-19.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2005-004623-19.